YARS2 Antibody

Code CSB-PA026246GA01HU
Size $600
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
YARS2
Alternative Names
CGI 04 antibody; FLJ13995 antibody; mitochondrial antibody; MLASA2 antibody; mt TyrRS antibody; SYYM_HUMAN antibody; Tyrosine tRNA ligase 2 mitochondrial antibody; Tyrosine tRNA ligase antibody; Tyrosine tRNA ligase mitochondrial antibody; Tyrosine--tRNA ligase antibody; Tyrosyl tRNA synthetase 2 mitochondrial antibody; Tyrosyl tRNA synthetase mitochondrial precursor antibody; Tyrosyl-tRNA synthetase antibody; TyrRS antibody; YARS 2 antibody; YARS2 antibody
Raised in
Rabbit
Species Reactivity
Human,Mouse,Rat
Immunogen
Human YARS2
Immunogen Species
Homo sapiens (Human)
Isotype
IgG
Purification Method
Antigen Affinity purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
PBS with 0.02% Sodium Azide, 50% Glycerol, pH 7.3. -20°C, Avoid freeze / thaw cycles.
Tested Applications
ELISA,WB,IHC
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Catalyzes the attachment of tyrosine to tRNA(Tyr) in a two-step reaction: tyrosine is first activated by ATP to form Tyr-AMP and then transferred to the acceptor end of tRNA(Tyr).
Gene References into Functions
  1. The p.Leu392Ser variant is likely a newly identified founder YARS2 mutation in mitochondrial myopathy. PMID: 28395030
  2. The mutation in YARS2 gene is a nuclear modifier for the phenotypic manifestation of Leber's hereditary optic neuropathy-associated mitochondrial DNA mutation. PMID: 26647310
  3. Data identified novel YARS2 mutations and noted marked phenotypic variability among YARS2 MLASA patients, with phenotypes ranging from mild to lethal, suggesting that the background mtDNA haplotype may be contributing to the phenotypic variability. PMID: 24344687
  4. The study confirms mutations in YARS2 as a cause of MLASA and shows that, like some of the cytoplasmic ARSs, mitochondrial ARSs occur in high-molecular-weight complexes. PMID: 22504945
  5. first example of a TyrRS lacking specificity toward N1-N72 and thus of a TyrRS disobeying the identity rules PMID: 15840810
  6. The YARS2 mutation reported here is an alternative cause of MLASA. PMID: 20598274
  7. The gene for mitochondrial tyrosyl-tRNA synthetase is described and the initial characterization of the enzyme is reported. Genes for the remaining missing synthetases have also been found with the exception of human glutaminyl-tRNA synthetase. PMID: 15779907
  8. the structure of a strictly mitochondrial human synthetase, namely tyrosyl-tRNA synthetase (mt-TyrRS), in complex with an adenylate analog at 2.2 A resolution PMID: 17997975
  9. the apparent occurrence of an unusual TG 3' splice site in intron 5 is discussed PMID: 17672918

Show More

Hide All

Involvement in disease
Myopathy with lactic acidosis and sideroblastic anemia 2 (MLASA2)
Subcellular Location
Mitochondrion matrix.
Protein Families
Class-I aminoacyl-tRNA synthetase family
Database Links

HGNC: 24249

OMIM: 610957

KEGG: hsa:51067

STRING: 9606.ENSP00000320658

UniGene: Hs.505231

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*